Immatics Future Growth
Future criteria checks 0/6
Immatics's revenue and earnings are forecast to decline at 5.6% and 22.8% per annum respectively while EPS is expected to decline by 17.1% per annum.
Key information
-22.8%
Earnings growth rate
-17.1%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | -5.6% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 25 Nov 2024 |
Recent future growth updates
Recent updates
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues
Sep 21Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
Jul 12Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 49 | -160 | -183 | N/A | 5 |
12/31/2025 | 62 | -137 | -144 | N/A | 7 |
12/31/2024 | 116 | -63 | -134 | N/A | 7 |
9/30/2024 | 116 | -56 | -45 | -20 | N/A |
6/30/2024 | 71 | -74 | -45 | -17 | N/A |
3/31/2024 | 74 | -80 | -26 | 9 | N/A |
12/31/2023 | 54 | -97 | -13 | 18 | N/A |
9/30/2023 | 76 | -84 | -117 | -92 | N/A |
6/30/2023 | 85 | -79 | -113 | -94 | N/A |
3/31/2023 | 80 | -68 | -40 | -31 | N/A |
12/31/2022 | 173 | 38 | 94 | 100 | N/A |
9/30/2022 | 151 | 34 | 97 | 102 | N/A |
6/30/2022 | 142 | 28 | 113 | 119 | N/A |
3/31/2022 | 130 | 15 | 38 | 44 | N/A |
12/31/2021 | 35 | -93 | -90 | -85 | N/A |
9/30/2021 | 28 | -95 | -86 | -81 | N/A |
6/30/2021 | 30 | -231 | -133 | -127 | N/A |
3/31/2021 | 32 | -226 | -97 | -91 | N/A |
12/31/2020 | 31 | -211 | -88 | -81 | N/A |
9/30/2020 | 26 | -208 | -38 | -31 | N/A |
6/30/2020 | 23 | -49 | 75 | 81 | N/A |
3/31/2020 | 22 | -34 | 55 | 60 | N/A |
12/31/2019 | 18 | -32 | 69 | 71 | N/A |
12/31/2018 | 4 | -31 | 20 | 21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMTX's revenue is expected to decline over the next 3 years (-5.6% per year).
High Growth Revenue: IMTX's revenue is forecast to decline over the next 3 years (-5.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 14:47 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immatics N.V. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Eric Schmidt | Cantor Fitzgerald & Co. |
Yevgeniya Livshits | Chardan Capital Markets, LLC |